腹腔灌注化疗药物和载体制剂的研究进展  

Advances in drug and carrier formulation for intraperitoneal perfusion chemotherapy

作　　者：张敏[1] 宋钟娟[1] 

机构地区：[1]复旦大学附属华东医院药剂科,上海200040

出　　处：《中国新药与临床杂志》2017年第6期319-323,共5页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：腹腔灌注化疗(IPC)是一种用于治疗原发性或转移性腹腔肿瘤的有效治疗方式。尽管IPC方式在临床使用多年,但在方案设计、滞留时间、药物和灌注液等选择方面缺乏标准流程。目前有多种研究在探讨优化IPC的药物载体,以期达到滞留时间长、不良反应少的治疗方式。本文将主要阐述IPC中化疗药物的选择以及药物新载体在IPC中的应用。Intraperitoneal perfusion chemotherapy carcinoma of the primary or metastases. Although IPC （IPC） is an effective way of treating peritoneal has been already performed for many years, no standardized treatment design has been developed in terms of schedule, residence time, drug, or carrier solution. A lot of researches are being performed to optimize IPC drug delivery to extend the residence time of therapy agent in the peritoneal cavity and decrease the adverse reaction of the cytotoxic agent. This paper reviewed chemotherapy drug selection and the recent advances made in drug delivery systems for IPC.

关 键 词：化学疗法 肿瘤 局部灌注 腹部肿瘤 药物载体 滞留时间 

分 类 号：R979.1[医药卫生—药品]